Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus donafenib and sintilimab for unresectable hepatocellular carcinoma
ChiCTR2200056206Phase 4Recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoint: Progression-Free Survival. Started Mar 2022; status: recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200056206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056206.